US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.43

-0.1200-4.71%

Post-market: 2.500.0700+2.88%19:46 EDT

Volume:180.86K

Turnover:446.37K

Market Cap:36.74M

PE:-0.76

High:2.58

Open:2.53

Low:2.43

Close:2.55

52wk High:10.00

52wk Low:2.13

Shares:15.12M

Float Shares:9.60M

Volume Ratio:1.31

T/O Rate:1.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1959

EPS(LYR):-2.9824

ROE:-107.62%

ROA:-60.80%

PB:1.60

PE(LYR):-0.81

Loading ...

Overview Company News Filings

CervoMed’s neflamapimod shows efficacy in dementia with DLB

BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology

CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL

CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology

THOMSON REUTERS

CervoMed Is Maintained at Buy by Chardan Capital

Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating

MT Newswires Live

CervoMed price target lowered to $11 from $19 at Roth Capital

Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)

CervoMed price target raised to $21 from $15 at Chardan

CervoMed Reports 2025 Results, Advances Neflamapimod Programs

CervoMed FY2025 net loss rose 66.67% to USD 27 million

BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates

CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang

CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate

Benzinga Earnings

Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target

CervoMed Is Maintained at Buy by D. Boral Capital

CervoMed Inc reports results for the quarter ended December 31 - Earnings Summary

Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/CRVO/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.43,"timestamp":1789761600000,"preClose":2.55,"halted":0,"volume":180861,"hourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.43,"latestTime":"19:46 EDT","volume":2267,"amount":5580.8563,"timestamp":1789775214516,"change":0.07,"changeRate":0.028807,"amplitude":0.028807},"delay":0,"changeRate":-0.04705882352941163,"floatShares":9604400,"shares":15119100,"eps":-3.195903,"marketStatus":"Market Closed","change":-0.12,"latestTime":"09-18 16:00:00 EDT","open":2.53,"high":2.5754,"low":2.43,"amount":446368.9088559,"amplitude":0.05702,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.55,"preHourTrading":{"tag":"盘前","latestPrice":2.53,"preClose":2.55,"latestTime":"09:17 EDT","volume":249,"amount":631.258824,"timestamp":1789737425843,"change":-0.02,"changeRate":-0.007843,"amplitude":0.047059},"postHourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.43,"latestTime":"19:46 EDT","volume":2267,"amount":5580.8563,"timestamp":1789775214516,"change":0.07,"changeRate":0.028807,"amplitude":0.028807},"volumeRatio":1.311322},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":9604400,"roa":"-60.80%","roe":"-107.62%","lyrEps":-2.982424,"volumeRatio":1.311322,"shares":15119100,"dividePrice":0,"high":2.5754,"amplitude":0.05702,"preClose":2.55,"low":2.43,"week52Low":2.13,"pbRate":"1.60","psRate":"110.90","week52High":10,"institutionHeld":0,"latestPrice":2.43,"eps":-3.195903,"divideRate":0,"volume":180861,"delay":0,"ttmEps":-3.195903,"open":2.53,"prevYearClose":7.9,"prevWeekClose":2.57,"prevMonthClose":2.63,"prevQuarterClose":3.1,"fiveDayClose":2.57,"twentyDayClose":2.56,"sixtyDayClose":3.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"CRVO","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-05-15","symbol":"CRVO","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2026-03-13","symbol":"CRVO","fiscalQuarterEnding":"2025/12","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773374400000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2025-11-07","symbol":"CRVO","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":6,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2026-09-17","current":-0.760348,"percent":0.960474,"low":-119.682483,"twenty":-32.435498,"median":-4.024859,"eighty":-1.528843,"high":-0.69356,"avg":-16.41222,"sd":23.111801,"marketCap":36890594},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-31","current":-2.909391,"twenty":-38.804612,"median":-7.450846,"eighty":-3.374238,"marketCap":65786832},{"date":"2025-11-07","current":-2.983046,"twenty":-38.663931,"median":-7.254628,"eighty":-3.361323,"marketCap":67452321},{"date":"2025-11-14","current":-2.621936,"twenty":-38.6419,"median":-7.20399,"eighty":-3.333221,"marketCap":67082212},{"date":"2025-11-21","current":-3.258434,"twenty":-38.625998,"median":-7.137979,"eighty":-3.315314,"marketCap":83366998},{"date":"2025-11-28","current":-3.594765,"twenty":-38.625995,"median":-6.963795,"eighty":-3.314496,"marketCap":91972026},{"date":"2025-12-05","current":-3.276516,"twenty":-38.456214,"median":-6.708179,"eighty":-3.314142,"marketCap":83829634},{"date":"2025-12-12","current":-2.961884,"twenty":-38.413768,"median":-6.632186,"eighty":-3.290836,"marketCap":75779768},{"date":"2025-12-19","current":-2.857006,"twenty":-38.350099,"median":-6.354912,"eighty":-3.258434,"marketCap":73096480},{"date":"2025-12-26","current":-3.066761,"twenty":-38.300453,"median":-6.221623,"eighty":-3.198527,"marketCap":78463057},{"date":"2026-01-02","current":-2.857006,"twenty":-38.248873,"median":-6.028218,"eighty":-3.184173,"marketCap":73096480},{"date":"2026-01-09","current":-2.846157,"twenty":-38.210281,"median":-5.866832,"eighty":-3.139814,"marketCap":72818898},{"date":"2026-01-16","current":-2.560456,"twenty":-38.170115,"median":-5.764162,"eighty":-3.103963,"marketCap":65509250},{"date":"2026-01-23","current":-2.379633,"twenty":-38.109126,"median":-5.691463,"eighty":-3.066761,"marketCap":60882891},{"date":"2026-01-30","current":-1.869712,"twenty":-37.999948,"median":-5.513005,"eighty":-3.019747,"marketCap":47836557},{"date":"2026-02-06","current":-1.663573,"twenty":-37.887707,"median":-5.323443,"eighty":-2.9876,"marketCap":42562507},{"date":"2026-02-13","current":-1.638258,"twenty":-37.814908,"median":-5.250814,"eighty":-2.957395,"marketCap":41914817},{"date":"2026-02-20","current":-1.89141,"twenty":-37.791053,"median":-5.231258,"eighty":-2.930623,"marketCap":48391720},{"date":"2026-02-27","current":-1.591244,"twenty":-37.763222,"median":-5.212816,"eighty":-2.89957,"marketCap":40711963},{"date":"2026-03-06","current":-1.450202,"twenty":-37.64792,"median":-5.171192,"eighty":-2.886661,"marketCap":37103403},{"date":"2026-03-13","current":-1.565929,"twenty":-37.601604,"median":-5.067362,"eighty":-2.872563,"marketCap":40064273},{"date":"2026-03-20","current":-1.452342,"twenty":-37.462974,"median":-5.060142,"eighty":-2.848327,"marketCap":39164381},{"date":"2026-03-27","current":-1.345905,"twenty":-37.39506,"median":-5.023312,"eighty":-2.81779,"marketCap":36294178},{"date":"2026-04-02","current":-1.373373,"twenty":-37.39506,"median":-5.008257,"eighty":-2.777444,"marketCap":37034876},{"date":"2026-04-10","current":-1.383673,"twenty":-37.352614,"median":-4.96552,"eighty":-2.744896,"marketCap":37312637},{"date":"2026-04-17","current":-1.369939,"twenty":-37.352614,"median":-4.878764,"eighty":-2.677991,"marketCap":36942288},{"date":"2026-04-24","current":-1.321871,"twenty":-37.289369,"median":-4.834638,"eighty":-2.621936,"marketCap":35646068},{"date":"2026-05-01","current":-1.266936,"twenty":-37.075389,"median":-4.791246,"eighty":-2.520675,"marketCap":34164673},{"date":"2026-05-08","current":-1.304704,"twenty":-37.013045,"median":-4.759848,"eighty":-2.379633,"marketCap":35183132},{"date":"2026-05-15","current":-1.29097,"twenty":-36.657918,"median":-4.726862,"eighty":-1.989055,"marketCap":34812783},{"date":"2026-05-22","current":-0.952489,"twenty":-36.618159,"median":-4.701084,"eighty":-1.869712,"marketCap":28609441},{"date":"2026-05-29","current":-0.967902,"twenty":-36.524547,"median":-4.684546,"eighty":-1.778577,"marketCap":29072377},{"date":"2026-06-05","current":-0.961737,"twenty":-36.333397,"median":-4.581202,"eighty":-1.73518,"marketCap":28887203},{"date":"2026-06-12","current":-0.752128,"twenty":-36.234746,"median":-4.538149,"eighty":-1.677316,"marketCap":22591274},{"date":"2026-06-18","current":-1.174429,"twenty":-36.1867,"median":-4.529194,"eighty":-1.658046,"marketCap":35275719},{"date":"2026-06-26","current":-1.508594,"twenty":-36.138654,"median":-4.51746,"eighty":-1.640428,"marketCap":45312880},{"date":"2026-07-02","current":-1.661705,"twenty":-35.994244,"median":-4.482916,"eighty":-1.622122,"marketCap":49911799},{"date":"2026-07-10","current":-1.684222,"twenty":-35.726787,"median":-4.41968,"eighty":-1.609687,"marketCap":50588111},{"date":"2026-07-17","current":-1.414026,"twenty":-35.527938,"median":-4.351268,"eighty":-1.601689,"marketCap":42472371},{"date":"2026-07-24","current":-1.202372,"twenty":-35.095242,"median":-4.262561,"eighty":-1.59587,"marketCap":36115042},{"date":"2026-07-31","current":-1.134823,"twenty":-34.627571,"median":-4.241728,"eighty":-1.588961,"marketCap":34086107},{"date":"2026-08-07","current":-1.242902,"twenty":-34.501534,"median":-4.181454,"eighty":-1.572341,"marketCap":37332403},{"date":"2026-08-14","current":-1.459615,"twenty":-34.113333,"median":-4.141074,"eighty":-1.56639,"marketCap":44298951},{"date":"2026-08-21","current":-1.275295,"twenty":-34.018436,"median":-4.117333,"eighty":-1.548892,"marketCap":38704885},{"date":"2026-08-28","current":-1.315148,"twenty":-33.795627,"median":-4.092569,"eighty":-1.540602,"marketCap":39914413},{"date":"2026-09-04","current":-1.265332,"twenty":-33.11242,"median":-4.089924,"eighty":-1.53948,"marketCap":38402503},{"date":"2026-09-11","current":-1.235442,"twenty":-32.960319,"median":-4.048287,"eighty":-1.533693,"marketCap":37495358},{"date":"2026-09-17","current":-1.215516,"twenty":-32.435498,"median":-4.024859,"eighty":-1.528843,"marketCap":36890594}],"updateTime":1789799261726},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620247143","title":"CervoMed’s neflamapimod shows efficacy in dementia with DLB","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247143?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:56","pubTimestamp":1773921377,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b Rewi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-shows-efficacy-in-dementia-with-dlb-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-shows-efficacy-in-dementia-with-dlb-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345774391.USD","BK4097","LU0205193047.USD","LU0240877869.USD","LU0345774631.USD","LU0205194284.USD","LU0240878834.USD","LU0348723411.USD","CRVO","DLB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247581","title":"BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247581","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247581?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:55","pubTimestamp":1773921319,"startTime":"0","endTime":"0","summary":"BRIEF-CervoMed Announces New Data At The Ad/Pd 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA9BMNHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426662","title":"CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426662?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:31","pubTimestamp":1773919887,"startTime":"0","endTime":"0","summary":"Investigators will present new analyses from CervoMed’s Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies at the AD/PD 2026 conference.In a within-participant comparison among patients who received placebo then DP Batch B, the CDR-SB difference was -1.11 at screening plasma pTau181 <21 pg/mL .In the extension phase, DP Batch B was associated with expected plasma drug concentration levels, while the initial randomized phase using DP Batch A did not reach expected levels.Across DP batches, 75% of DP Batch B participants versus 50% of DP Batch A participants reached the 4 ng/mL trough threshold .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9kX3YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","NDAQ","BK4585","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014013.SGD","CRVO","SG9999014039.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620572242","title":"CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2620572242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620572242?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA9BMNHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255807","title":"CervoMed Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255807?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:29","pubTimestamp":1773836940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 08:29 ET (12:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620723420","title":"Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723420","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723420?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829491,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of buy and mean price target of $22.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401340","title":"CervoMed price target lowered to $11 from $19 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401340?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:00","pubTimestamp":1773788426,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620640957","title":"Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620640957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620640957?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:35","pubTimestamp":1773786922,"startTime":"0","endTime":"0","summary":"In a report released today, Daniil Gataulin from Chardan Capital maintained a Buy rating on CervoMed, with a price target of $21.00. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620409623","title":"CervoMed price target raised to $21 from $15 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620409623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620409623?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:25","pubTimestamp":1773786346,"startTime":"0","endTime":"0","summary":"Chardan raised the firm’s price target on CervoMed (CRVO) to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620180405","title":"CervoMed Reports 2025 Results, Advances Neflamapimod Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620180405","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620180405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:04","pubTimestamp":1773781497,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an update. On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040351","title":"CervoMed FY2025 net loss rose 66.67% to USD 27 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040351?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779716,"startTime":"0","endTime":"0","summary":"CervoMed filed a Form 8-K reporting fourth-quarter and full-year 2025 results and corporate updates. Cash, cash equivalents and marketable securities were USD 20.9 million at Dec. 31, 2025, and the company said this is expected to fund operating expenses and capital expenditure for about six months. Full-year grant revenue fell 59% to USD 4 million, reflecting the completion of the randomized phase of the RewinD-LB trial in late 2024 and the extension phase in mid-2025. Full-year R&D expenses rose 16% to USD 21.8 million, driven by higher personnel and consulting costs, CMC work tied to RewinD-LB batch issues and pre-Phase 3 manufacturing improvements, and expenses for the RAS and nfvPPA trials initiated in 2025. Full-year net loss widened to USD 27 million and G&A expenses increased to USD 10.5 million, while CEO John Alam said CervoMed plans to initiate a single global Phase 3 DLB trial in the second half of 2026 subject to funding and expects multiple catalysts in the second half of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9TY297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424336","title":"BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424336","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424336?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:07","pubTimestamp":1773749241,"startTime":"0","endTime":"0","summary":"BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate UpdatesMarch 17 (Reuters) - CervoMed Inc CRVO.O:CERVOMED REPORTS FOURTH QUARTER AND FULL YEAR 2025 FIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA2GTFVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620212364","title":"CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2620212364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620212364?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:55","pubTimestamp":1773748516,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed, with a price target of $27.00. Sumant K...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-compelling-neflamapimod-opportunity-and-undervalued-shares-despite-near-term-funding-overhang-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-compelling-neflamapimod-opportunity-and-undervalued-shares-despite-near-term-funding-overhang-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620838421","title":"CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620838421","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620838421?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:43","pubTimestamp":1773747794,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.63) by 40.13 percent. This is a 10 percent decrease over losses of $(0.80) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51292056/cervomed-q4-eps-0-88-misses-0-63-estimate-sales-8-726m-beat-966-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620142949","title":"Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620142949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620142949?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026. Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen. Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis. BOSTON, March 17, 2026  -- CervoMed Inc. , a clinical-stage biotechnology company developing treatments for age-related brain disorders , today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0205193047.USD","LU0205194284.USD","LU0345774631.USD","BK4233","BK4205","BK4528","CRVO","LU0240877869.USD","UK","LU0240878834.USD","LU0345774391.USD","LU0348723411.USD","BK4097","DLB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620423474","title":"CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620423474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620423474?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:16","pubTimestamp":1773742577,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on CRVO stock, giving a Buy rating on March 5. Ram Selvaraju has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-validated-phase-2b-data-de-risked-pivotal-pathway-and-solid-cash-runway-underpin-reiterated-buy-and-25-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-validated-phase-2b-data-de-risked-pivotal-pathway-and-solid-cash-runway-underpin-reiterated-buy-and-25-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221495","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221495?lang=en_us&edition=fundamental","pubTime":"2026-03-17 03:16","pubTimestamp":1773688560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 15:16 ET (19:16 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619466627","title":"CervoMed Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2619466627","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619466627?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:31","pubTimestamp":1773667901,"startTime":"0","endTime":"0","summary":"CervoMed Inc reports results for the quarter ended December 31 - Earnings SummaryCervoMed Inc CRVO.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended December 31, lower ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N4041AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619038177","title":"Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2619038177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619038177?lang=en_us&edition=fundamental","pubTime":"2026-03-15 14:01","pubTimestamp":1773554519,"startTime":"0","endTime":"0","summary":"Cervomed Inc. (CRVO) has disclosed a new risk, in the Manufacturing category. Cervomed Inc. faces the risk that changes in manufacturing methods or...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/manufacturing-and-formulation-changes-threaten-cervomeds-neflamapimod-development-timeline-and-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/manufacturing-and-formulation-changes-threaten-cervomeds-neflamapimod-development-timeline-and-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":119,"code":"91000000","status":"200"}]}}